Premium Deucravacitinib API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Deucravacitinib (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Selective Tyrosine Kinase 2 (TYK2) Inhibitor

Indications: Moderate-to-Severe Plaque Psoriasis

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Deucravacitinib distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Deucravacitinib is a highly advanced, first-in-class small-molecule Active Pharmaceutical Ingredient (API). In the field of immunology and dermatological pharmacology, it is classified as an oral, highly selective tyrosine kinase 2 (TYK2) inhibitor. For pharmaceutical manufacturers, this API represents a critical shift away from broad-spectrum immunosuppressants toward highly targeted cytokine suppression.

The pharmacological mechanism of Deucravacitinib is distinct from legacy Janus kinase (JAK) inhibitors. Standard JAK inhibitors bind to the highly conserved active catalytic domain (JH1) at the ATP-binding site, which often leads to the cross-inhibition of JAK1, JAK2, and JAK3. In contrast, Deucravacitinib acts via allosteric inhibition. It binds specifically to the regulatory pseudokinase domain (JH2) of the TYK2 enzyme.

By binding to this regulatory pocket, the API forces a conformational change that locks the TYK2 enzyme in an inactive state. This highly selective blockade prevents the intracellular signal transduction of specific pro-inflammatory cytokines—namely Interleukin-23 (IL-23), Interleukin-12 (IL-12), and Type I interferons. Because IL-23 is the primary driver of the TH17 cellular response responsible for epidermal hyperproliferation, inhibiting this pathway effectively suppresses plaque psoriasis.

For formulation scientists, integrating this active ingredient allows for the development of a highly targeted oral therapeutic with a substantially improved safety profile compared to non-selective JAK inhibitors. In commercial settings, this API is typically formulated into 6 mg oral solid film-coated tablets.

Sourcing DEUCRAVACITNIB Pakistan: Morgan’s Supply Network

Commercializing next-generation targeted synthetic therapies requires an unbroken, fully traceable raw material pipeline. Procuring specialty immunology APIs for local manufacturing often involves navigating extended international lead times, unpredictable customs bottlenecks, and highly complex regulatory frameworks. Sourcing DEUCRAVACITNIB Pakistan through Morgan’s localized distribution network successfully mitigates these systemic supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from premier global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary API vendor secures several operational advantages for your facility:

• DRAP Registration Support: Morgan facilitates the secure transfer of all critical regulatory documentation required for local compliance. This includes the open part of the Drug Master File (DMF), comprehensive impurity and degradant profiles, and accelerated stability data to support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized inventory management eliminates international freight variables. Whether you require a pilot batch for R&D or are scaling up a high-volume DEUCRAVACITNIB api Pakistan procurement order, we guarantee your commercial batch schedules are met without costly manufacturing delays.
• Batch-to-Batch Uniformity: Every API delivery provided by Morgan includes a rigorously verified Certificate of Analysis (CoA) from the source manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during dry blending, granulation, and tablet compression.

Technical Specifications for QA & R&D

The Deucravacitinib API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards. Notably, the molecule features a unique deuterated structural component to enhance metabolic stability.

• Chemical Name: 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
• CAS Number: 1609392-27-9
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C20H19D3N8O3
• Molecular Weight: 425.47 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Solubility is highly pH-dependent, increasing as the pH of the solvent decreases. Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist analytical R&D teams with dissolution profiling.

Manufacturing and Handling Guidelines for Formulators

Deucravacitinib is a highly potent immunomodulatory compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent chemical degradation.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure containment isolators to prevent the inhalation of airborne particulates and cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.